Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Identification of a Wilms’ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Van Driessche A, Berneman ZN, Van Tendeloo VF . Active specific immunotherapy targeting the Wilms’ tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012; 17: 250–259.

    Article  CAS  Google Scholar 

  2. Anguille S, Van Tendeloo VF, Berneman ZN . Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; e-pub ahead of print 6 July 2012; doi:10.1038/leu.2012.145.

    Article  CAS  Google Scholar 

  3. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890.

    Article  CAS  Google Scholar 

  4. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242.

    Article  CAS  Google Scholar 

  5. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW et al. A clinicaland immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113: 6541–6548.

    Article  CAS  Google Scholar 

  6. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107: 13824–13829.

    Article  CAS  Google Scholar 

  7. Tsuboi A, Oka Y, Kyo T, Katayama Y, Elisseeva OA, Kawakami M et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 2012; 26: 1410–1413.

    Article  CAS  Google Scholar 

  8. Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VFI . Dendritic cell vaccine therapy for acute myeloid leukemia Questions and answers. Hum Vaccines 2011; 7: 579–584.

    Article  CAS  Google Scholar 

  9. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA et al. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells. Microbiol Immunol 2008; 52: 591–600.

    Article  CAS  Google Scholar 

  10. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR . Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39: D913–D919.

    Article  CAS  Google Scholar 

  11. Williams F, Meenagh A, Single R, McNally M, Kelly P, Nelson MP et al. High resolution HLA-DRB1 identification of a caucasian population. Hum Immunol 2004; 65: 66–77.

    Article  CAS  Google Scholar 

  12. Chattopadhyay PK, Yu J, Roederer M . A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005; 11: 1113–1117.

    Article  CAS  Google Scholar 

  13. Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G et al. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res 2009; 15: 4467–4474.

    Article  CAS  Google Scholar 

  14. Faner R, James E, Huston L, Pujol-Borrel R, Kwok WW, Juan M . Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation. Eur J Immunol 2010; 40: 91–102.

    Article  CAS  Google Scholar 

  15. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N et al. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res 2010; 30: 2247–2254.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was made possible by funding from the Belgian National Cancer Plan (initiative 29), the Research Foundation–Flanders (FWO), the Belgian Foundation against Cancer and the Belgian public utility foundation VOCATIO. SA is a former PhD fellow of FWO and currently holds an Emmanuel van der Schueren Fellowship of the Flemish League against Cancer. ES is a postdoctoral researcher granted by FWO. This study was also supported, in part, by a Grant-in-Aid for Young Scientists (WAKATE B-22700896) from the Ministry of Education, Science, Sports, Culture and Technology, and the Ministry of Health, Labor and Welfare of Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Anguille.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anguille, S., Fujiki, F., Smits, E. et al. Identification of a Wilms’ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes. Leukemia 27, 748–750 (2013). https://doi.org/10.1038/leu.2012.248

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.248

This article is cited by

Search

Quick links